- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CVS Demands Cost Control for Novel Cholesterol Treatments
Two PCSK9 inhibitors under development-one by Amgen and the other jointly by Sanofi and Regeneron-could eventually cost the US healthcare system $150 billion per year. William Shrank, the chief scientific officer of CVS thinks these costs would be unsustainable for the healthcare industry that is already rattled by the burgeoning cost of specialty medications.
CVS Health on Tuesday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place."
CVS, the second largest U.S. pharmacy benefit manager which negotiates drug prices for 65 million people through contracts with employers and health plans, noted that two of the new injectable cholesterol fighters - called PCSK9 inhibitors - could be approved by mid-2015 and likely each cost $7,000 to $12,000 a year.
All told, PCSK9 inhibitors could eventually cost the healthcare system as much as $150 billion a year and become the highest-selling class of drugs in history, CVS said.
"The resilience and ability of our healthcare system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place," William Shrank, chief scientific officer for CVS, said in a statement.
Read the complete article on Reuters:
The high cost of hepatitis C medications and their inclusion on formularies was the topic of discussion during a recent panel discussion held by The American Journal of Managed Care.
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
